By continuing on our website, you agree to our use of the cookie for statistical and personalization purpose.
Large pharmaceutical companies say allowing Medicare to negotiate lower drug prices will stifle innovation in drug development. Read a new op-ed in Harvard Business Review to find out why that’s not so.
Senior Associate, Wynne Health Group
Publication / Apr 26, 2021
Blog / Mar 23, 2021